BACK SITE

Future Worthy of Expectations – Rapid Bladder Cancer Antibody Detection

-AIAM

Bladder cancer is a malignant tumor that occurs on the bladder mucosa, and it is one of the top ten most common tumors in the world. In Western countries, its incidence is second only to prostate cancer, and accounting for the first in the incidence of urogenital tumors in China.

In the past, the main method for diagnosing bladder cancer was cystoscopy, and cystoscopy biopsy was performed when necessary. Because the cystoscopy is a metal surgical instrument, the inspection requires a catheter in the urethra, which will damage the mucous membrane during the operation. After the inspection, the patient often will have symptoms such as urethral burning pain, hematuria, frequent urination and dysuria. If the aseptic operation is not strict, it will cause urinary tract infection, the known incidence of urinary tract infection after cystoscopy is 5%, and the missed detection rate of cystoscopy can reach 30% at present. In addition, bladder cancer patients require lifelong follow-up, long-term use of cystoscopy is more painful, therefore, the current clinical need for a non-invasive, economical, repeatable, high detection rate and low misdiagnosis rate for the diagnosis of bladder cancer.

With the advancement of science and technology, it is discovered that the main part of bladder cancer is immersed in urine, and the products secreted by cancer cells and necrotic apoptotic cells are also excreted in urine. Therefore, the detection of tumor markers by urine should be a convenient and noninvasive method. Bladder Cancer BLCA-4 Protein Urine Rapid Detection Card has the characteristics of rapidness, high sensitivity, strong specificity, good stability, simple operation and no need for any instrument and equipment. The result of the judgment is intuitive and reliable, easy to master, providing a convenient and reliable method for large-scale population screening for bladder cancer and self-detection of patients after operation of bladder cancer. At the same time, it also facilitates the detection of patients in remote areas, and solves the consequences caused by patients who refuse to be examined because of fear of pain.